載入中
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
前收盤價
US$20.84
+US$0.47 · +2.31%
盤中時間採用ET。市場資料可能有所延遲。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日內區間
目前US$20.84
52週區間
目前US$20.84
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
47
合理估值
情緒
49
多空交錯
風險
52
風險偏高
動能
69
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日內區間
目前US$20.84
52週區間
目前US$20.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 27.23億 USD | 26.96億 USD | 28.43億 USD | 28.37億 USD | 30.58億 USD |
| 銷貨成本 | 22.98億 USD | 21.62億 USD | 22.52億 USD | 21.13億 USD | 24.53億 USD |
| 毛利 | 4.26億 USD | 5.34億 USD | 5.91億 USD | 7.24億 USD | 6.04億 USD |
| 銷售、一般及管理費用 | 4.56億 USD | 5.61億 USD | 4.48億 USD | 4.16億 USD | 3.03億 USD |
| 營業費用 | 4.56億 USD | 6.96億 USD | 5.59億 USD | 5.37億 USD | 4.9億 USD |
| 利息支出 | 9140萬 USD | 1.24億 USD | 6980萬 USD | 20萬 USD | 20萬 USD |
| 折舊和攤銷 | 7800萬 USD | 8690萬 USD | 9800萬 USD | 9360萬 USD | 1.66億 USD |
| 營業利益 | −3060萬 USD | −1.62億 USD | 3200萬 USD | 1.87億 USD | 1.14億 USD |
| 淨利 | −9.86億 USD | −3.29億 USD | −2520萬 USD | 1.86億 USD | 9800萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.50
下跌空間 1.63%報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.16億0.11%1031.91億 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI5503.14萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM5172.59萬0.07%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF2014.51萬0.02%954億 USD0.05%US$235+0.80%
Vanguard Morningstar Small-Cap ETFVB1997.3萬0.01%1853億 USD0.03%US$289.48+0.64%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1781.75萬0.11%158.4億 USD0.03%US$53.45+0.17%
Invesco S&P SmallCap Momentum ETFXSMO1744.46萬0.61%28.69億 USD0.35%US$81.75+0.57%
Schwab Fundamental U.S. Small Company Index ETFFNDA1616.2萬0.18%87.82億 USD0.25%US$35.62+0.17%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMInvesco S&P SmallCap Momentum ETFXSMOSchwab Fundamental U.S. Small Company Index ETFFNDAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
